|
321 (2005 rank: 258)
BMY
43,000 |
|
Peter R. Dolan
345 Park Ave., New York, NY 10154
212-546-4000
http://www.bms.com |
|
Revenues |
20,222.0 |
-7.6 |
Profits |
3,000.0 |
25.6 |
Assets |
28,138.0 |
-- |
Stockholders' Equity |
11,208.0 |
-- |
Industry: Pharmaceuticals |
1 |
Pfizer |
101 |
51,353 |
2 |
Johnson & Johnson |
104 |
50,514 |
3 |
GlaxoSmithKline |
143 |
39,366 |
4 |
Sanofi-Aventis |
159 |
35,429 |
5 |
Novartis |
177 |
32,212 |
6 |
Roche Group |
204 |
28,496 |
7 |
AstraZeneca |
253 |
23,950 |
8 |
Abbott Laboratories |
283 |
22,338 |
9 |
Merck |
289 |
22,012 |
10 |
Bristol-Myers Squibb |
321 |
20,222 |
11 |
Wyeth |
343 |
18,756 |
12 |
Eli Lilly |
464 |
14,645 |
From the July 24, 2006 issue
|
How the Countries Stack Up |
United States |
170 |
Japan |
70 |
Britain, France (tied) |
38 |
See the rest |
Most profitable companies |
|